NxThera, Inc.
USPTO PatentsView assignee record - 9 granted patents across 2 technology areas, recorded in grant years 2015–2019. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).
The verdict
According to USPTO PatentsView, Nxthera ranks #29,649 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 2 technology areas.
- #29,649
- of 49,997 US assignees by volume
- 13th percentile
- by Innovation Score (23.6/100)
- 17.8
- avg claims per patent
- -100%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R29649 · US Corporation #29,649 · 9 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 9 grants
- MID-PACK #29,649/49,997
- PHOTO-FINISH Nordock
- CPC-NARROW A61B · 2 areas
- INNOV-THIN 23.6/100
- CLAIMS-RICH 17.8 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -100% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Nordock, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Nxthera’s 23.6 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Nxthera
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- NxThera · this assignee 24
NxThera · this assignee
24 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Nxthera's Innovation Score is 23.6/100 (13th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Nxthera?
Each dot is one of Nxthera’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Nxthera’s own 17.8 claims/patent is ABOVE the 16.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Nxthera's grants concentrate
NxThera, Inc. is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2019 (3 grants) versus a trough of 1 in 2015. By volume, Nxthera sits between Nordock, Inc. and OB Realty, LLC.
Who files at NxThera's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Nordock
Nordock, Inc.
9 patents
- Northeast Electri…
Northeast Electric Power University
9 patents
- Northern Internat…
Northern Technologies International Corporation
9 patents
- Northwest A & F U…
Northwest A & F University
9 patents
- Nylok
Nylok LLC
9 patents
- Nypromold
NyproMold Inc.
9 patents
- O-net Communicati…
O-net Communications (SHENZHEN) Limited
9 patents
- OB Realty
OB Realty, LLC
9 patents
- Nxthera ◀
NxThera, Inc.
9 patents
What this shows NxThera holds 9 patents at rank #29,624, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near NxThera
By rank, the assignees closest to #29,624 in granted patent volume.
- Nordock, Inc. #29,620 · 9 patents
- Northeast Electric Power University #29,621 · 9 patents
- Northern Technologies International Corporation #29,622 · 9 patents
- Northwest A & F University #29,623 · 9 patents
- Nylok LLC #29,625 · 9 patents
- NyproMold Inc. #29,626 · 9 patents
- O-net Communications (SHENZHEN) Limited #29,627 · 9 patents
- OB Realty, LLC #29,628 · 9 patents
Leaders in A61B (Diagnosis)
Other assignees with the most granted patents in NxThera's primary technology class.
- Covidien LP 5,709 in class
- Koniniklijke Philips N.V. 3,414 in class
- Olympus Corporation 2,758 in class
- Boston Scientific Scimed, Inc. 2,362 in class
- Cilag GmbH International 2,063 in class
- Intuitive Surgical Operations, Inc. 1,921 in class
- DePuy Synthes Products, Inc. 1,796 in class
- Ethicon, Inc. 1,762 in class
Nxthera's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
24 13th percentile higher than 13% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 11.1% |
| 2016 | 2 | 22.2% |
| 2017 | 1 | 11.1% |
| 2018 | 2 | 22.2% |
| 2019 | 3 | 33.3% |
Which technologies does NxThera, Inc. patent most?
Top 2 of 2 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
NxThera, Inc.'s patent record in context - here's where to go next.
- NxThera, Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 100% of its portfolio - see every assignee active in that class. Explore A61B
- Ranked #29,649 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare NxThera, Inc. against Nordock, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 23.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.